Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TECR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TECR Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TECR Products |
| Gene Delivery | TECR Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TECR Products |
| Benchmark Ab | Anti-TECR Antibody Recombinant positive control for Western Blot/IHC. |
View TECR Products |
| Validator | TECR siRNA Set For knockdown verification. |
View TECR Products |
| Related Target A | ELOVL6 Key fatty acid elongase working upstream of TECR in VLCFA synthesis. |
View ELOVL6 Products |
| Related Target B | ELOVL1 Elongase regulating long-chain fatty acid synthesis, synergistic pathway. |
View ELOVL1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass ER membrane protein conformation preservation | Lentivirus Premade Particles for stable cell line generation to enable cell-based functional assays |
| Off-target screening against similar reductases | High-purity recombinant homolog proteins strictly verified by mass spec for counter-screening |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live TECR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TECR therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule inhibitors and RNA-targeting modalities. As first-generation lipid metabolism therapies reach the clinic, the next wave of R&D is targeting the microsomal fatty acid elongation pathway to treat solid tumors and metabolic syndromes.
TECR (Trans-2,3-enoyl-CoA reductase) is an essential endoplasmic reticulum (ER) resident enzyme catalyzing the final step of the very-long-chain fatty acid (VLCFA) elongation cycle. Elevated TECR activity is strongly associated with prostate, colon, and breast cancers, where it sustains rapid membrane biogenesis and lipid raft-mediated signaling. Consequently, developing highly selective inhibitors that disrupt this pathway without triggering systemic metabolic toxicity is a primary focus for drug developers.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Academic & Biotech Consortia | Prostate Cancer, Colon Cancer | High-throughput Screening (Need Lentivirus for Stable Cell Lines & Cell-based Assays) |
| RNAi / Antisense | Lipid Metabolism Researchers | Metabolic Disorders, MRT14 Research | Knockdown Validation (Need High-specificity siRNA & qPCR Primers) |
| Recombinant Enzymes | Biochemical Assay Developers | Enzymatic Screening | Pure Protein Fragments / Detergent-solubilized Full-length Proteins |